Platelet activating factor and tracheobronchial respiratory glycoconjugate release in feline and human explants: involvement of the lipoxygenase pathway.
It has been suggested that platelet activating factor (PAF) may participate in many aspects of bronchial asthma, including stimulation of mucus secretion. Feline tracheal and human bronchial explant production of respiratory glycoconjugates (RGC) in response to platelet activating factor (PAF) was investigated, in order to differentiate the actions of this putative mediator on mucus secretion. PAF caused a dose-dependent increase in RGC release in concentrations ranging from 100-0.5 microM during a 1-2 hours incubation with either feline or human explants, and the effect was inhibited by the PAF receptor antagonists Ro 19-3704. Several lines of evidence suggest that PAF enhances RGC release indirectly through stimulation of the production of lipoxygenase metabolites of arachidonic acid. 1) Incubation of 10 microM PAF together with arachidonic acid (100 micrograms/ml) enhances PAF's stimulatory effect on RGC release in cats. 2) The cyclooxygenase inhibitor ibuprofen (65 and 420 microM) either failed to effect or slightly enhanced PAF induced RGC release in both species. 3) The combined cyclooxygenase and lipoxygenase inhibitor nordihydroguaiaretic acid (NDGA) as well as the putatively specific 5-lipoxygenase inhibitor L-651,392 (both at 50 microM) inhibited the response to PAF in both species. 4) The putative LTD4 receptor antagonists (L-660,711, 100 microM) slightly reduced the PAF secretory response in human bronchi. We conclude that PAF causes specific receptor mediated RGC release. This response is indirectly mediated through the generation of lipoxygenase metabolite formation including 5-lipoxygenase pathway metabolites.
Lundgren
J D
JD
Critical Care Medicine Department, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Kaliner
M
M
Logun
C
C
Shelhamer
J H
JH
D000818:Animals; D001980:Bronchi / Q000378:metabolism*; D002415:Cats; D046508:Culture Techniques; D005995:Glyceryl Ethers / Q000494:pharmacology; D006001:Glycoconjugates / Q000378:metabolism*; D006801:Humans; D007052:Ibuprofen / Q000494:pharmacology; D008084:Lipoxygenase / Q000378:metabolism*; D009637:Masoprocol / Q000494:pharmacology; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors / Q000502:physiology*; D013844:Thiazoles / Q000494:pharmacology; D014132:Trachea / Q000378:metabolism*; D014316:Tritium
D005995:Glyceryl Ethers; D006001:Glycoconjugates; D010972:Platelet Activating Factor; D013844:Thiazoles; D014316:Tritium; C053235:Ro 19-3704; D009637:Masoprocol; D008084:Lipoxygenase; D007052:Ibuprofen